Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Eligibility Criteria

• * Patients must have castrate refractory prostate cancer with prior taxane treatment (docetaxel or cabazitaxel) which was used in the castrate refractory setting
• * Cancer Progression as defined by PCWG3
• * Age 18 or older.
• * ECOG 0, 1, or 2
• * Life expectancy of greater than 2 months
• * Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
• * Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
• * Organ \& marrow function as defined below: Absolute neutrophil count \>1,200/mcL Platelets \>75,000/mcL; total bilirubin= within normal institutional limits; AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal; creatinine \<2.5 X institutional upper limit of normal
• * Patients may not be receiving any other investigational agents.
• * History of allergic reactions attributed to compounds of similar chemical or biologic composition to omeprazole or taxane therapy.
• * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.